News 11 high-impact drugs to look out for in 2026 Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.
News Wegovy pill shows strong early uptake, as rival looms Encouraging early sales data for oral Wegovy has buoyed Novo Nordisk, as Lilly waits for an FDA decision on its rival orforglipron, now due in Q2.
News JPM: Illumina launches 'unprecedented' disease biology atlas Illumina says its new Billion Cell Atlas can be used to identify and validate drug targets and train AI models used in drug discovery.
News Abivax climbs on Lilly takeover speculation Shares in Abivax were tracking up this morning as a media report in France suggested it could see a €15bn takeover offer from Eli Lilly.
News Rumour confirmed as Lilly buys Ventyx for $1.2 billion Eli Lilly has agreed a $1.2bn takeover of Ventyx Bio and its clinical-stage drugs for inflammatory and cardiometabolic diseases.
News Lilly taps Nimbus for another obesity candidate For a second time, Eli Lilly has turned to Boston biotech Nimbus Therapeutics to add a potential weight loss therapy to its pipeline.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.